Asarina Pharma (private company)

See something wrong or missing? Let us know
Offices:
Stockholm
Business model:
B2B
Investors:
we tracked 4 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 3 transactions

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Asarina Pharma, formerly known as Umecrine Mood, is based on state-of-the-art science from Umeå University, Sweden. The founder, Torbjörn Bäckström, MD and PhD, senior professor at the Department of Clinical Science, Obstetrics and Gynecology, Umeå University as well as head of the Umeå  Neurosteroid Research Center, started Umecrine Mood together with the Karolinska Institutet innovation system in 2006 and the company became Asarina Pharma in 2015.

Asarina Pharma focuses on the development of Sepranolone (UC1010) for the treatment of premenstrual dysphoric disorder and other menstrually related conditions, which has shown promising results in an exploratory clinical Phase I/II study.

Companies with similar profile to Asarina Pharma:

CompanyCriteria
Sweden OxThera
65%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • At least one vc investor: Kurma Life Science Partners
  • At least one other investor: Idinvest Partners
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Modus Therapeutics
45%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Rosetta Capital
  • Minim one investor from outside Scandinavia: Yes
Norway Vaccibody
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Denmark Orphazyme
44%
  • Similar business models: B2B
  • At least one vc investor: Kurma Life Science Partners
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Iceland 3Z Pharmaceuticals
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Finland Synoste Oy
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Norway Oncoinvent
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Finland Glucostratus (Mendor)
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Finland Blueprint Genetics
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Finland BC Platforms
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Sweden AMRA
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Irras
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Denmark Acarix
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Finland Valkee
43%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Vironova
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Sweden Trialbee
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Norway Avexxin
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Sweden Athera
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Sweden Ilya Pharma
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Finland Optomed
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes